Open AccessSelinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
Author(s) -
Baljevic Muhamed,
Gasparetto Cristina,
Schiller Gary J.,
Tuchman Sascha A.,
Callander Natalie S.,
Lentzsch Suzanne,
Monge Jorge,
Kotb Rami,
Bahlis Nizar J.,
White Darrell,
Chen Christine I.,
Sutherland Heather J.,
Madan Sumit,
LeBlanc Richard,
Sebag Michael,
Venner Christopher P.,
Bensinger William I.,
Biran Noa,
DeCastro Andrew,
Van Domelen Dane R.,
Zhang Chris,
Shah Jatin J.,
Shacham Sharon,
Kauffman Michael G.,
Bentur Ohad S.,
Lipe Brea
Publication year - 2022
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.572
Subject(s) - multiple myeloma , chimeric antigen receptor , medicine , antigen , oncology , antibody , immunology , t cell , pharmacology , immune system
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti‐BCMA‐targeted chimeric antigen receptor‐T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA‐antibody‐drug conjugate therapy. We observe that X‐containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients’ prior anti‐BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X‐based regimens following broader anti‐BCMA therapy.